Literature DB >> 36149588

Treatments against Polymorphosal discrepancies in Glioblastoma Multiforme.

Swastika Maitra1, Biswajit Chakraborty2, Sumira Malik3, Athanasios Alexiou4,5, Nobendu Mukerjee6,7, Subhradeep Roy8, Shaswata Modak8, Mohammad Mehedi Hasan9, Arabinda Ghosh10, Asmita Ghosh11, Mohammad Amjad Kamal12,13,14,15, Abhijit Dey16, Ghulam Md Ashraf17,18, Md Habibur Rahman19, Badrah S Alghamdi17,20, Adel Mohammad Abuzenadah13,21.   

Abstract

Glioblastoma (GB) are aggressive tumors that obstruct normal brain function. While the skull cannot expand in response to cancer growth, the growing pressure in the brain is generally the first sign. It can produce more frequent headaches, unexplained nausea or vomiting, blurred peripheral vision, double vision, a loss of feeling or movement in an arm or leg, and difficulty speaking and concentrating; all depend on the tumor's location. GB can also cause vascular thrombi, damaging endothelial cells and leading to red blood cell leakage. Latest studies have revealed the role of single nucleotide polymorphisms (SNPs) in developing and spreading cancers such as GB and breast cancer. Many discovered SNPs are associated with GB, particularly in great abundance in the promoter region, creating polygenetic vulnerability to glioma. This study aims to compile a list of some of the most frequent and significant SNPs implicated with GB formation and proliferation.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Epidermal growth factors receptor; Glioblastoma; Single nucleotide polymorphisms; Tumors

Year:  2022        PMID: 36149588     DOI: 10.1007/s11011-022-01082-6

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.655


  29 in total

Review 1.  Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake.

Authors:  Erik R Abels; Xandra O Breakefield
Journal:  Cell Mol Neurobiol       Date:  2016-04-06       Impact factor: 5.046

Review 2.  Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.

Authors:  Jose A Carrillo; Claudia A Munoz
Journal:  Neurosurg Clin N Am       Date:  2012-02-18       Impact factor: 2.509

3.  Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype.

Authors:  H Gréen; I J Falk; K Lotfi; E Paul; M Hermansson; R Rosenquist; C Paul; H Nahi
Journal:  Pharmacogenomics J       Date:  2010-10-12       Impact factor: 3.550

4.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma.

Authors:  A V Brenner; M A Butler; S S Wang; A M Ruder; N Rothman; P A Schulte; S J Chanock; H A Fine; M S Linet; P D Inskip
Journal:  Carcinogenesis       Date:  2007-10-04       Impact factor: 4.944

6.  Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

Authors:  Tim Forshew; Ruth G Tatevossian; Andrew R J Lawson; Jing Ma; Geoff Neale; Babatunji W Ogunkolade; Tania A Jones; Johan Aarum; James Dalton; Simon Bailey; Tracy Chaplin; Rowena L Carter; Amar Gajjar; Alberto Broniscer; Bryan D Young; David W Ellison; Denise Sheer
Journal:  J Pathol       Date:  2009-06       Impact factor: 7.996

7.  Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

Authors:  Jennifer L Clarke; Fabio M Iwamoto; Joohee Sul; Katherine Panageas; Andrew B Lassman; Lisa M DeAngelis; Adília Hormigo; Craig P Nolan; Igor Gavrilovic; Sasan Karimi; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

8.  IDH1 and IDH2 mutations in gliomas.

Authors:  Emilie De Carli; Xiaowei Wang; Stéphanie Puget
Journal:  N Engl J Med       Date:  2009-05-21       Impact factor: 176.079

9.  Mapping of deletion and translocation breakpoints in 1q44 implicates the serine/threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum.

Authors:  Elena Boland; Jill Clayton-Smith; Victoria G Woo; Shane McKee; Forbes D C Manson; Livija Medne; Elaine Zackai; Eric A Swanson; David Fitzpatrick; Kathleen J Millen; Elliott H Sherr; William B Dobyns; Graeme C M Black
Journal:  Am J Hum Genet       Date:  2007-06-13       Impact factor: 11.025

Review 10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Adam L Cohen; Sheri L Holmen; Howard Colman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 6.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.